retatrutide safety trial results Looking forward to when #retatrutide's Phase 3 will become available. There are are 4 planned TRIUMPH trials investigating retatrutide's efficacy in treating obesity and its complications: #type2diabetes #cardiovascular disease retatrutide clinical trial retatrutide drug

The trial involved 338 participants measuring the change in body weight from baseline to 24 weeks

Wegovy is available in five different pre-filled, single-dose syringes including 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg

Discontinued formulations Efpeglenatide and taspoglutide Efpeglenatide and taspoglutide were once-promising, long-acting GLP-1 receptor agonists developed for the treatment of T2DM, both designed for once-weekly administration

When selecting a GLP-1 medication for a patient with Hashimoto's thyroiditis, there is no single "best" GLP-1 agonist specifically for this population

In GLUTag cells, we demonstrated that a high glucose level with L-glutamine and sodium butyrate, which are major physiological nutrients, stimulated GLP-1 secretion and increased cAMP accumulation

While GLP-1 agonists are not prohibited, their use in weight-class sports raises ethical questions about artificially manipulating body weight for competitive advantage